Inhibitors of HMG-CoA reductase: Current and future prospects

Narender Singh; Joaquín Tamariz; Germán Chamorro; Jose L. Medina-Franco

doi:10.2174/138955709789878105

Inhibitors of HMG-CoA reductase: Current and future prospects

Narender Singh, Joaquín Tamariz, Germán Chamorro, Jose L. Medina-Franco

Escuela Nacional de Ciencias Biológicas (ENCB)

Research output: Contribution to journal › Short survey › peer-review

24 Scopus citations

Abstract

High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

Original language	English
Pages (from-to)	1272-1283
Number of pages	12
Journal	Mini-Reviews in Medicinal Chemistry
Volume	9
Issue number	11
DOIs	https://doi.org/10.2174/138955709789878105
State	Published - 2009

Keywords

3-hydroxy-3-methylglutaryl-coenzyme A reductase
Cardiovascular disease
Cholesterol
Low density lipoproteins
Side effects
Statins
Structure-based drug design
α-asarone

Access to Document

10.2174/138955709789878105

Cite this

@article{f3d6de5d41bd4da1b9b8ba0e90371670,

title = "Inhibitors of HMG-CoA reductase: Current and future prospects",

abstract = "High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.",

keywords = "3-hydroxy-3-methylglutaryl-coenzyme A reductase, Cardiovascular disease, Cholesterol, Low density lipoproteins, Side effects, Statins, Structure-based drug design, α-asarone",

author = "Narender Singh and Joaqu{\'i}n Tamariz and Germ{\'a}n Chamorro and Medina-Franco, {Jose L.}",

year = "2009",

doi = "10.2174/138955709789878105",

language = "Ingl{\'e}s",

volume = "9",

pages = "1272--1283",

journal = "Mini-Reviews in Medicinal Chemistry",

issn = "1389-5575",

number = "11",

}

TY - JOUR

T1 - Inhibitors of HMG-CoA reductase

T2 - Current and future prospects

AU - Singh, Narender

AU - Tamariz, Joaquín

AU - Chamorro, Germán

AU - Medina-Franco, Jose L.

PY - 2009

Y1 - 2009

N2 - High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

AB - High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

KW - 3-hydroxy-3-methylglutaryl-coenzyme A reductase

KW - Cardiovascular disease

KW - Cholesterol

KW - Low density lipoproteins

KW - Side effects

KW - Statins

KW - Structure-based drug design

KW - α-asarone

UR - http://www.scopus.com/inward/record.url?scp=73349085890&partnerID=8YFLogxK

U2 - 10.2174/138955709789878105

DO - 10.2174/138955709789878105

M3 - Estudio breve

SN - 1389-5575

VL - 9

SP - 1272

EP - 1283

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

IS - 11

ER -

Inhibitors of HMG-CoA reductase: Current and future prospects

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this